Uslu Muhittin, Corum Orhan, Yazar Enver
Department of Laboratory and Veterinary Health, Sefaatli Vocational College, University of Yozgat Bozok, Yozgat, Türkiye.
Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, University of Hatay Mustafa Kemal, Hatay, Türkiye.
Vet Med Sci. 2025 Sep;11(5):e70462. doi: 10.1002/vms3.70462.
The objective of this study was to investigate the effect of meloxicam on the pharmacokinetics of cefquinome in experimental endotoxemic sheep. In addition, the MIC of cefquinome was determined against Escherichia coli, Pasteurella multocida, Klebsiella pneumoniae, and Mannheimia haemolytica.
The study was carried out on six sheep in three periods according to a longitudinal pharmacokinetic design. Cefquinome (2.5 mg/kg, IV, CFQ) was administered in the first period, cefquinome+meloxicam (1 mg/kg, IV, CFQ+MLX) in the second period, and lipopolysaccharide (20 µg/kg, IV, LPS+CFQ+MLX)+meloxicam+cefquinome in the third period. Plasma cefquinome concentrations were assayed using HPLC-UV, and pharmacokinetic data were calculated by a two-compartment open model.
Following a single IV injection of cefquinome, the t, V, and Cl values were 1.12 h, 0.21 L/kg, and 0.17 L/h/kg, respectively. The t was prolonged from 1.12 to 2.79 h in the LPS+CFQ+MLX group. While V was increased (from 0.21 to 0.36 L/kg) in the LPS+CFQ+MLX group, Cl decreased (from 0.17 to 0.10 L/h/kg) in the CFQ+MLX and LPS+CFQ+MLX groups. The MICs of cefquinome were 0.031 to 0.063 µg/mL for E. coli, M. haemolytica, and K. pneumoniae and 0.016 to 1 µg/mL for P. multocida. At a 12 h dosing interval, the CFQ, CFQ+MLX, and LPS+CFQ+MLX groups attained a T > MIC ratio of 40% for bacteria with MIC values of ≤ 0.50, ≤ 1, and ≤ 1 µg/mL, respectively.
These results indicate that combined administration of meloxicam alters the pharmacokinetics and therapeutic efficacy of cefquinome in experimental endotoxemic sheep.
本研究旨在探讨美洛昔康对实验性内毒素血症绵羊中头孢喹肟药代动力学的影响。此外,还测定了头孢喹肟对大肠杆菌、多杀性巴氏杆菌、肺炎克雷伯菌和溶血曼氏杆菌的最低抑菌浓度(MIC)。
根据纵向药代动力学设计,对6只绵羊分三个阶段进行研究。第一阶段静脉注射头孢喹肟(2.5mg/kg,IV,CFQ),第二阶段静脉注射头孢喹肟+美洛昔康(1mg/kg,IV,CFQ+MLX),第三阶段静脉注射脂多糖(20μg/kg,IV,LPS+CFQ+MLX)+美洛昔康+头孢喹肟。采用高效液相色谱-紫外法测定血浆中头孢喹肟浓度,并通过二室开放模型计算药代动力学数据。
单次静脉注射头孢喹肟后,t、V和Cl值分别为1.12小时、0.21L/kg和0.17L/h/kg。在LPS+CFQ+MLX组中,t从1.12小时延长至2.79小时。在LPS+CFQ+MLX组中V增加(从0.21升至0.36L/kg),而在CFQ+MLX组和LPS+CFQ+MLX组中Cl降低(从0.17降至0.10L/h/kg)。头孢喹肟对大肠杆菌、溶血曼氏杆菌和肺炎克雷伯菌的MIC为0.031至0.063μg/mL,对多杀性巴氏杆菌的MIC为0.016至1μg/mL。在12小时给药间隔时,CFQ组、CFQ+MLX组和LPS+CFQ+MLX组对于MIC值≤0.50μg/mL、≤1μg/mL和≤1μg/mL的细菌,T>MIC比率分别达到40%。
这些结果表明,在实验性内毒素血症绵羊中,联合使用美洛昔康会改变头孢喹肟的药代动力学和治疗效果。